Tech Company Inital Public Offerings
Allakos IPO
Allakos was purchased by . Shares became public on 7/18/2018.
Transaction Overview
Company Name
Announced On
7/18/2018
Transaction Type
IPO
Amount
$129,600,000
Proceeds Purpose
The company will use the IPO proceeds to continue development of its lead compound, AK002.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
975 Island Dr. 201
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Website
Email Address
Overview
Allakos (Nasdaq: ALLK) is a biotechnology company developing antibodies targeting receptors that modulate the activity of immune effector cells involved in inflammation and tissue damage.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Alexander
Chief Medical Officer
Henrik Rasmussen
Chief Operating Officer
Adam Tomasi
VP - Bus. Development
Simon Greenwood
VP - General Counsel
Mark Asbury
VP - Regulatory Affairs
Sally Bolmer
Browse more venture capital transactions:
Prev: 7/18/2018: Verodin venture capital transaction
Next: 7/18/2018: Spiffy venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs